menu
    • menu
    [{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"National University Hospital, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic NKG2DL-targeting CAR-Gamma Delta T Cell","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ National University Hospital, Singapore","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ National University Hospital, Singapore"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ Benchmark Company","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Benchmark Company"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"SunAct Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ SunAct Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ SunAct Cancer Institute"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"CytoMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ CytoMed Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ CytoMed Therapeutics"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"NKG2DL-CAR-gamma-delta T cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CytoMed Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Therapeutics \/ Sengkang General Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by CytoMed Therapeutics

    Menu

    CytoMed Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : SunAct Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CytoMed Signs Collaboration with SunAct for Gamma Delta T Cells in Cancer

                            Details : The collaboration aims to advance use of allogeneic off-the-shelf Gamma Delta T Cells, CTM-N2D therapy, for treatment of solid cancers in a proposed Phase 2 clinical trial in India.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : SunAct Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoMed Begins Phase I CAR-Gamma Delta T Cell Therapy Trial in Solid Tumors & Malignancies

                            Details : CTM-N2D is being evaluated in a clinical trial that tests allogeneic NKG2DL-targeting CAR gamma delta T cells in patients with advanced solid tumors or hematological malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 20, 2024

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : Sengkang General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CytoMed Therapeutics Collaborates with Singapore Hospital for Stem Cell Research

                            Details : A collaboration aims to prove the concept of an injectable cartilage regeneration therapy using umbilical cord-derived mesenchymal stem cells for knee injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : Sengkang General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-...

                            Details : This collaboration aims to develop new treatment modalities by using gamma-delta T cells (gdTc) for the treatment of acute myeloid leukemia (AML) and breast cancer patients at an affordable cost.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Benchmark Company

                            Deal Size : $9.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

                            Details : The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate and to continue technology development of the Company's iPSC-gdNKT product candidate.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 13, 2023

                            Lead Product(s) : CTM-N2D

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Benchmark Company

                            Deal Size : $9.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic NKG2DL-targeting CAR-Gamma Delta T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National University Hospital, Singapore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

                            Details : Allogeneic NKG2DL-targeting CAR-Gamma Delta T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Allogeneic NKG2DL-targeting CAR-Gamma Delta T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National University Hospital, Singapore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Mesenchymal Stem Cell

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Landmark Medical Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSC Infusion for Anti-aging and Regenerative Therapy

                            Details : Human Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 22, 2019

                            Lead Product(s) : Human Mesenchymal Stem Cell

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Landmark Medical Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKG2DL-CAR-gamma-delta T cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refract...

                            Details : NKG2DL-CAR-gamma-delta T cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 27, 2019

                            Lead Product(s) : NKG2DL-CAR-gamma-delta T cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth